Table 3.
Information on comorbidities and prescription medications recorded for the linked sample. Column 1: information recorded in the CHHiP trial at baseline (pre-radiotherapy), Column 2: information in primary care before enrolment to the CHHiP trial and Column 5: information in primary care after enrolment to the CHHiP trial. Date of the trial enrolment was defined as the start date of androgen deprivation therapy. Columns 3 and 4: information not recorded in each of the databases respectively
| Information recorded at baseline in the CHHiP trial n (%) |
Information recorded in primary care before enrolment to CHHiP n (%) |
Not recoded in the trial n (%) |
Not recorded in primary care n (%) |
Information recorded in primary care after enrolment to CHHiP n (%) (new diagnosis) |
|
|---|---|---|---|---|---|
| Past clinical history of comorbidity | |||||
| Diabetes | 9 (8) |
11 (10) (type1–1, type2–10) |
2 (2) | 0 |
12 (11) (all participants type2) |
| Hypertension | 38 (36) | 40 (38) | 14 (13) | 12 (11) | 9 (8) |
| Inflammatory bowel disease | 2 (2) | Not extracted | – | – | – |
| Symptomatic haemorrhoids | 5 (5) | 5 (5) | 5 (5) | 5 (5) | 14 (13) |
| Previous pelvic surgery / prostatectomy | 8 (7) | 14 (13) | 11 (10) | 5 (5) | 3 (3) |
| Previous transurethral resection of the prostate | 16 (15) | 52 (49) | 38 (36) | 2 (2) | 3 (3) |
| Medication | |||||
| Alpha-blocker or anticholinergic | 12 (11) | 9 (8) | 8 (7) | 11 (10) | 16 (15) |
| Angiotensin converting enzyme inhibitors | Not recorded | 22 (20) | 22 (21) | – | 15 (14) |
| Statins | Not recorded | 40 (38) | 40 (38) | – | 25 (24) |
| Metformin | Not recorded | 7 (7) | 7 (7) | – | 7 (7) |
| Aspirin | Not recorded | 32 (30) | 32 (30) | – | 12 (11) |
| Phosphodiesterase type 5 inhibitors | Not recorded | 20 (19) | 20 (19) | – | 26 (25) |
| Rectal steroids | Not recorded | 7 (7) | 7 (7) | – | 17 (16) |